Samir has made groundbreaking contributions to the field of biological barriers and drug delivery. His research, which is focused on the fundamental understanding of biological barriers, has led to the development of new materials and technologies for diagnosis and treatment of various ailments including diabetes, cancer, cardiovascular diseases, skin conditions and infections. Many of his technologies have advanced to human clinical studies and products. Samir’s technical contributions are in the area of drug delivery and include the development of unique bio-inspired nanoparticles with engineered shapes and mechanical properties that exhibit enhanced circulation and targeting to cancer and inflamed endothelium. He has also developed novel bio-synthetic hybrid systems that use synthetic nanoparticles hitchhiking on circulatory cells to avoid immune clearance and allow delivery to tissues. Specifically in transdermal drug delivery, Samir has established a fundamental knowledge-base of transport properties of skin and has pioneered a large number of technologies including low-frequency ultrasound, pulsed microjet injector, and high throughput screening (INSIGHT). He has also established an understanding of the effect of penetration enhancers on permeation across the intestinal epithelium and has invented novel technologies, in particular intestinal patches and a novel permeation enhancer (PPS) for oral delivery of proteins such as insulin and calcitonin.
Samir is the author of more than 210 publications in the area of drug delivery and biomaterials, has given close to 500 invited and contributed presentations worldwide, and is an inventor on more than 150 pending or issued patents. He is a co-founder of several companies that are developing therapeutic or diagnostic products based on his inventions.
Samir is an elected member of the National Academies of Engineering and Medicine, and elected fellow of the American Institute of Medical and Biological Engineering, the American Association for the Advancement of Science, the National Academy of Inventors, the Controlled Release Society, the Biomedical Engineering Society, and the American Association of Pharmaceutical Scientists. He is a Thomson Reuters Highly Cited Researcher. He serves on the editorial boards of several journals and currently serves as Editor-in-Chief of Bioengineering and Translational Medicine.